An interventional study of Egg White Pudding and Nestle Resource in Sarcopenia in Elderly, sponsored by Seven Oaks Hospital Chronic Disease Innovation Centre. Recruiting at 1 site in Canada. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Seven Oaks Hospital Chronic Disease Innovation Centre · Not applicable, Interventional, and Treatment
Among 40 studies in Sarcopenia with a site in Canada — 7 open to participants now, 9 under way, none of them phase 3. Sarcopenia · Canada.
Among the 40 studies in Sarcopenia with a site in Canada, this one is the 11th largest by planned enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2026, is one of 28 with no phase, and was the 39th registered.
1,329 studies on the registry are indexed under Sarcopenia; 420 are open to participants now.
Browse Sarcopenia studies →7 of the 40 studies in Sarcopenia with a site in Canada are open now. Recruiting first, the newest first:
British Columbia Cancer Agency · Sites in Canada
University of Saskatchewan · Sites in Canada
University of Regina · Sites in Canada
McMaster University · Sites in Canada
University of Toronto · Sites in Canada
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 247 Sarcopenia studies recruiting now, 153 (62%) set no upper age limit and 33 (13%) stop at 75 or younger; 9 take children under 18; 65 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 54 is close to the median of 60 across 855 interventional studies indexed under Sarcopenia.
Median enrollment 40 across the 35 interventional studies, 146 across the 5 observational. Of the 24 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 40 have an industry lead sponsor. The 10 most frequent:
Seven Oaks Hospital Chronic Disease Innovation Centre is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Seven Oaks Hospital Chronic Disease Innovation Centre has 1 study filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
3 of the studies in Sarcopenia with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06630949McMaster UniversityD3-Creatine and Skeletal Muscle in Older Adults | 2026-12-31 |
| NCT07805993Seven Oaks Hospital Chronic Disease Innovation CentreFeasibility of Egg White Pudding Supplementation for Individuals in Personal Care Home Centres Needing Dietary Supplementation | 2027-02 |
| NCT07625202University of SaskatchewanCreatine Supplementation During GLP-1a Therapy | 2027-05-30 |
Among the 40 studies in Sarcopenia with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial is an open-label randomized controlled parallel arm feasibility trial. 54 residents in care homes receiving nutrition supplementation (minimum 40% of each sex, ≥ 50 years of age). Participants will receive the egg white pudding (experimental) or a standard currently provided dietary supplement (control) on a daily basis and will be advised to follow any dietary recommendations they receive from their care team. Participants will be recruited at personal care homes throughout Winnipeg. Study visits will take place with a study coordinator at baseline and at 8 weeks (endpoint). Product acceptability will be assessed through dietary logs. This study has been reviewed and approved by The Committee for Harmonized Health Impact, Privacy, and Ethics Review (CHIPER).
This trial is an open-label randomized controlled parallel arm feasibility trial. 54 residents from non-shared health personal care home centres (target of a minimum 40% of each sex, ≥ 50 years of age) will be recruited. Participants will receive the egg white pudding (experimental) 5 days a week or a standard currently provided dietary supplement (control) 7 days a week and will be advised to follow any dietary recommendations they receive from their care team. The personal care home team will approach residents or their ADM to participate in the research. Once a potential participant confirms interest, the research team will approach them for scheduling a screening visit. As part of the screening process, the care team may provide the research team with information on the participant's MDS (Minimum Data Set) level, which is routinely collected by personal care homes in Canada (levels 1-3). This information will be recorded at the screening visit for descriptive purposes only and will not be used to exclude any participants. The research coordinator and research assistant will also oversee and document the dispensing of products, which will be administered by the care team at the home care centre. After the screening visit, study visits will take place with a research coordinator or research assistant at Week 1 (baseline) and at Week 8 (endpoint). Product acceptability will be assessed through feedback questionnaire.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Resource 2.0
Dietary Supplement: Nestle Resource
Egg White Pudding
Dietary Supplement: Egg White Pudding
Participants will be given a high protein egg white pudding 5 days a week for 8 weeks.
Participants in the control group will be given 180 ml of Resource 2.0 seven days a week for 8 weeks.
Hand Grip Strength
Hand grip strength will be measured using a specialized handheld device called a hand dynamometer that records the maximum isometric force generated in kilograms or pounds.
Time frame: 8 weeks
Waist circumference
The study staff will wrap a flexible tape measure around participants' middle at the level of the belly button or just above the hip bones.
Time frame: 8 weeks
Body weight
Body weight will be measured by participants stepping onto a digital or mechanical weighing scale placed on a hard, flat surface
Time frame: 8 weeks
Calf Circumference
The study staff will wrap a flexible tape measure around the widest part of participants' lower leg while keeping the tape snug but comfortable.
Time frame: 8 weeks
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Jun 2026 (actual). Primary completion is estimated for Feb 2027, 8 months after the start.
Of 492 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 8 months is below that.
Counting every sponsor, half of 503 studies reached it within 18 months; a quarter within 8 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seven Oaks Hospital Chronic Disease Innovation Centre